Sign In
Buy CSBR
$5.69
-0.0350 (-0.611%)
At Close: Jun 03, 2026
Champions Oncology (CSBR) Q4 2025 Earnings Call Transcript
07:55am, Friday, 25'th Jul 2025
Champions Oncology (NASDAQ:CSBR ) Q4 2025 Earnings Call July 23, 2025 4:30 PM ET Company Participants David Barry Miller - Chief Financial Officer Ronnie Morris - CEO & Director Conference Call Partic
Champions Oncology Reports Record Annual Revenue of $57 Million
04:00pm, Wednesday, 23'rd Jul 2025
Total annual revenue growth of 14% HACKENSACK, NJ / ACCESS Newswire / July 23, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced it
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025
08:30am, Monday, 21'st Jul 2025
HACKENSACK, NJ / ACCESS Newswire / July 21, 2025 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report
Champions Oncology Announces Appointment of New CEO
08:30am, Friday, 18'th Jul 2025
HACKENSACK, NJ / ACCESS Newswire / July 18, 2025 / Champions Oncology (NASDAQ:CSBR), a leading provider of oncology-focused CRO services specializing in preclinical and clinical specialty testing, tod
Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models
08:30am, Tuesday, 08'th Jul 2025
Expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models HACKENSACK, NJ / ACCESS Newswire / July 8, 2025 / Champio
Champions Oncology: Biological IP Is The Real Asset - Not Preclinical Services
02:47pm, Monday, 16'th Jun 2025
Champions Oncology is transitioning from a traditional CRO to also a high-margin data licensing platform, unlocking new revenue and margin potential. The market undervalues CSBR, not reflecting its ev
Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
09:45am, Monday, 28'th Apr 2025
HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinica
Champions Oncology, Inc. (CSBR) Q3 2025 Earnings Call Transcript
08:07pm, Tuesday, 11'th Mar 2025
Champions Oncology, Inc. (NASDAQ:CSBR ) Q3 2025 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Maj Soueidan
Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million
03:55pm, Tuesday, 11'th Mar 2025
HACKENSACK, NJ / ACCESS Newswire / March 11, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, toda
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025
04:00pm, Thursday, 06'th Mar 2025
HACKENSACK, NJ / ACCESS Newswire / March 6, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will
HACKENSACK, NJ / ACCESS Newswire / February 18, 2025 / Champions Oncology Inc. (NASDAQ:CSBR), a global leader in preclinical oncology research and clinical specialty testing, today announced the accep
Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership
08:00am, Wednesday, 08'th Jan 2025
HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to annou
Champions Oncology: Right Point To Own In The Cycle Thanks To Operating Efficiencies
09:00am, Friday, 27'th Dec 2024
Champoins Oncology broke out of a multiyear downtrend following its Q2'25 earnings. Management has embarked on a one-way journey to reduce working capital and grow the business with zero incremental c
Champions Oncology, Inc. (CSBR) Q2 2025 Earnings Call Transcript
06:02pm, Wednesday, 11'th Dec 2024
Champions Oncology, Inc. (NASDAQ:CSBR ) Q3 2024 Earnings Conference Call December 11, 2024 4:30 PM ET Company Participants Ronnie Morris - Chief Executive Officer David Miller - Chief Financial Office
Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million
04:00pm, Wednesday, 11'th Dec 2024
HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today
